Skip to main content

Table 2 Patient characteristics over time

From: Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction

 

GROUP C (2011)

GROUP C (2014)

p-value

patients (n)

total

1083

n/a

gender (%)

male

584 (53.9%)

n/a

female

470 (43.4%)

undetermined

29 (2.7%)

age (years)

Median (IQR)

75 (68–81)

78 (71–84)

n/a

Min – Max

24–93

27–96

< 65

200 (18.5%)

145 (13.4%)

65–74

321 (29.6%)

241 (22.3%)

≥75

562 (51.9%)

697 (64.4%)

 

additional diagnosis

patients With at least 1

1003 (92.6%)

986 (91.0%)

.13a

renal insufficiency

61 (5.6%)

65 (6.0%)

.77a

coagulopathy

17 (1.6%)

17 (1.6%)

1.0a

intracranial bleeding

4 (0.4%)

5 (0.5%)

1.0a

epistaxis

21 (1.9%)

14 (1.3%)

.30a

gastrointestinal bleeding

13 (1.2%)

17 (1.6%)

.59a

stroke

33 (3.0%)

28 (2.6%)

.58a

CHA2DS2-VASC:

0

92 (8.5%)

59 (5.4%)

<.01a

1

100 (9.2%)

87 (8.0%)

≥2

884 (81.6)

908 (83.8%)

not computable

7 (0.6%)

29 (2.7%)

n/a

prescriptions (per year)

total

1056 (97.5%)

1064 (98.2%)

n/a

M (SD)

19.4 (14.6)

22.6 (16.5)

<.01b

Min - Max

1–118

1–115

all patients including those without prescription

  

<.01b

M (SD)

18.8 (14.8)

22.0 (16.7)

Min - Max

0–118

0–115

OAC1

VKA or NOAC

382 (35.3%)

600 (55.4%)

<.01a

VKA

373 (34.4%)

387 (35.7%)

.41a

Rivaroxaban

3 (0.3%)

181 (16.7%)

<.01a

Dabigatran

7 (0.6%)

23 (2.1%)

<.01a

Apixaban

none

28 (2.6%)

n/c

ASA (without additional OAC)2

136 (12.6%)

97 (9.0%)

<.01a

consultation of cardiologist

245 (22.6%)

262 (24.2%)

.32a

  1. CONTENT-Patients with diagnosis of atrial fibrillation, which were observed over time including data from 2011 and follow-up in 2014 (group C). OAC = oral anticoagulation, VKA = vitamin-k antagonists, NOAC = novel oral anticoagulation, ASA = Acetylsalicylic acid
  2. 1Different prescriptions per year such as VKA and NOAC or NOAC and NOAC was possible (n = 29)
  3. 2Indication for ASA (100 mg), such as peripheral vascular disease or post-stroke or post-myocardial infarction or else and either as primary or secondary prophylaxis, could not clearly be stated
  4. aMcNemar test, b t-test for dependent samples